2024

• Tu, S., Li, T., Carroll, A., Mahoney, C., Huynh, W., Park, S., Henderson, R., Vucic, S., Kiernan, M., Lin, C. (2024). Central neurodegeneration in Kennedy’s disease accompanies peripheral motor dysfunction. Scientific Reports, 14(1). [More Information]
• Li, T., Trinh, T., Bosco, A., Kiernan, M., Goldstein, D., Park, S. (2024). Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes. Supportive Care in Cancer, 32(5), 278. [More Information]
• Alberti, P., Li, T., Park, S., Nathan, P., Tamburin, S., Thomas, S., Smith, E., Argyriou, A., Bruna, J., Damaj, M., et al (2024). Considerations for establishing and maintaining international research collaboration: the example of chemotherapy-induced peripheral neurotoxicity (CIPN)—a white paper. Supportive Care in Cancer, 32(2), 117. [More Information]
• Mahfouz, F., Li, T., Timmins, H., Horvath, L., Harrison, M., Grimison, P., Marx, G., Goldstein, D., Park, S. (2024). Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity. JNCCN Journal of the National Comprehensive Cancer Network, 22(2), 108-116. [More Information]
• Yeung, N., Li, T., Lin, H., Timmins, H., Goldstein, D., Harrison, M., Friedlander, M., Mahon, K., Giles, C., Meikle, P., Park, S., Horvath, L. (2024). Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy. JCO Precision Oncology, 8. [More Information]

2023

• Timmins, H., Mizrahi, D., Li, T., Kiernan, M., Goldstein, D., Park, S. (2023). Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. Journal of Cancer Survivorship, 17(1), 222-236. [More Information]
• Li, T., Timmins, H., Trinh, T., Mizrahi, D., Harrison, M., Horvath, L., Grimison, P., Friedlander, M., Kiernan, M., King, M., Rutherford, C., Park, S., et al (2023). Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes. JNCCN Journal of the National Comprehensive Cancer Network, 21(2), 125-132. [More Information]
• Mizrahi, D., Goldstein, D., Trinh, T., Li, T., Timmins, H., Harrison, M., Marx, G., Hovey, E., Lewis, C., Friedlander, M., Park, S. (2023). Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy. Asia-Pacific Journal of Clinical Oncology, 19(1), 243-249. [More Information]
• Li, T., Kandula, T., Cohn, R., Kiernan, M., Park, S., Farrar, M. (2023). Prospective assessment of vincristine-induced peripheral neuropathy in paediatric acute lymphoblastic leukemia. Clinical Neurophysiology, 154, 157-168. [More Information]

2022

• Li, T., Park, S., Battaglini, E., King, M., Kiernan, M., Goldstein, D., Rutherford, C. (2022). Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. Quality of Life Research, 31(11), 3091-3107. [More Information]
• Mahfouz, F., Park, S., Li, T., Timmins, H., Horvath, L., Harrison, M., Grimison, P., King, T., Goldstein, D., Mizrahi, D. (2022). Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients. Clinical Autonomic Research, 32(6), 497-506. [More Information]
• Bérubé-Mercier, P., Tapp, D., Cimon, M., Li, T., Park, S., Bouhêlier, É., McGarragle, K., Robichaud, L., Gewandter, J., Bouchard, M., et al (2022). Evaluation of the psychometric properties of patient-reported and clinician-reported outcome measures of chemotherapy-induced peripheral neuropathy: a COSMIN systematic review protocol. BMJ Open, 12(4), e057950-1-e057950-7. [More Information]
• Hooshmand, K., Goldstein, D., Timmins, H., Li, T., Harrison, M., Friedlander, M., Lewis, C., Lees, J., Moalem-Taylor, G., Guennewig, B., Park, S., Kwok, J. (2022). Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study. Journal of Translational Medicine, 20(1). [More Information]
• Park, S., Li, T., Kiernan, M., Garg, N., Wilson, I., White, R., Boggild, M., McNabb, A., Lee-Archer, M., Taylor, B. (2022). Prevalence of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in two regions of Australia. Muscle and Nerve, 66(5), 576-582. [More Information]

2021

• Li, T., Mizrahi, D., Goldstein, D., Kiernan, M., Park, S. (2021). Chemotherapy and peripheral neuropathy. Neurological Sciences, 42(10), 4109-4121. [More Information]
• Mizrahi, D., Park, S., Li, T., Timmins, H., Trinh, T., Au, K., Battaglini, E., Wyld, D., Henderson, R., Grimison, P., et al (2021). Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. JAMA Network Open, 4(2), e2036695. [More Information]
• Timmins, H., Li, T., Goldstein, D., Trinh, T., Mizrahi, D., Harrison, M., Horvath, L., Friedlander, M., Kiernan, M., Park, S. (2021). The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. Journal of Cancer Survivorship, 16(2), 223-232.
• Timmins, H., Li, T., Trinh, T., Kiernan, M., Harrison, M., Boyle, F., Friedlander, M., Goldstein, D., Park, S. (2021). Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. The Oncologist, 26(5), 366-374. [More Information]

2020

• Li, T., Timmins, H., King, T., Kiernan, M., Goldstein, D., Park, S. (2020). Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials. Hematological Oncology, 38(3), 229-243. [More Information]
• Timmins, H., Li, T., Huynh, W., Kiernan, M., Baron-Hay, S., Boyle, F., Goldstein, D., Park, S. (2020). Electrophysiological and phenotypic profiles of taxane-induced neuropathy. Clinical Neurophysiology, 131(8), 1979-1985. [More Information]
• Timmins, H., Li, T., Park, S. (2020). Evaluation of Neuropathic Pain in Chemotherapy Treated Patients. In Wolfgang Grisold, Riccardo Soffietti, Stefan Oberndorfer and Guido Cavaletti (Eds.), Effects of Cancer Treatment on the Nervous System, Volume 1, (pp. 255-280). United Kingdom: Cambridge Scholars Publishing.
• Li, T., Timmins, H., Lazarus, H., Park, S. (2020). Peripheral neuropathy in hematologic malignancies – Past, present and future. Blood Reviews, 43, 100653. [More Information]
• Timmins, H., Li, T., Kiernan, M., Horvath, L., Goldstein, D., Park, S. (2020). Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. The Journal of Pain, 21(1-Feb), 44-58. [More Information]
• Timmins, H., Li, T., Kiernan, M., Baron-Hay, S., Marx, G., Boyle, F., Goldstein, D., Park, S. (2020). Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. Supportive Care in Cancer, 28(9), 4459-4466. [More Information]

2019

• McCrary, J., Goldstein, D., Trinh, T., Timmins, H., Li, T., Menant, J., Friedlander, M., Lewis, C., Hertzberg, M., O’Neill, S., King, T., Park, S., et al (2019). Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments. JNCCN Journal of the National Comprehensive Cancer Network, 17(8), 949-955. [More Information]
• McCrary, J., Goldstein, D., Sandler, C., Barry, B., Marthick, M., Timmins, H., Li, T., Horvath, L., Grimison, P., Park, S. (2019). Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer, 27(10), 3849-3857. [More Information]
• McCrary, J., Goldstein, D., Trinh, T., Timmins, H., Li, T., Friedlander, M., Bosco, A., Harrison, M., Maier, N., O'Neill, S., Park, S. (2019). Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. Journal of Pain and Symptom Management, 58(6), 1023-1032. [More Information]

2018

• Noto, Y., Garg, N., Li, T., Timmins, H., Park, S., Shibuya, K., Shahrizaila, N., Huynh, W., Matamala, J., Dharmadasa, T., Yiannikas, K., Vucic, S., Kiernan, M. (2018). Comparison of cross-sectional areas and distal-proximal nerve ratios in amyotrophic lateral sclerosis. Muscle and Nerve, 58(6), 777-783. [More Information]